SCI时时刷

search
+
Systemic chemokine-modulatory regimen combined with neoadjuvant chemotherapy in patients with triple-negative breast cancer
Patient accrual details and demographicsFrom December 2019 to March 2022, 12 patients were consented. Three patients did n...
Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events
ColitisIMC is the second most common of all irAEs and often the most severe.42 It is also the most common irAE identified ...
FOXA1 enhances antitumor immunity via repressing interferon-induced PD-L1 expression in nasopharyngeal carcinoma
IntroductionNasopharyngeal carcinoma (NPC) is a malignant cancer originating from nasopharynx epithelium. NPC is prevalent...
DLL4-targeted CAR-T therapy sensitizes neoadjuvant chemotherapy via eliminating cancer stem cells and reshaping immune microenvironment in HER2+ breast cancer
BackgroundHuman epidermal growth factor receptor 2 (HER2) is overexpressed in 15–20% of invasive breast cancers (BCs).1 2 ...
Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression
BackgroundCytotoxic CD8+ T cells can specifically recognize and eliminate cancer cells when detecting tumor-derived antige...
Depletion of conventional CD4+ T cells is required for robust priming and dissemination of tumor antigen-specific CD8+ T cells in the setting of anti-CD4 therapy
BackgroundTreatment with monocolonal anti-CD4 antibodies has long been used to deplete regulatory T cells (Tregs) and elic...
Magnitude of antigen-specific T-cell immunity the month after completing vaccination series predicts the development of long-term persistence of antitumor immune response
WHAT IS ALREADY KNOWN ON THIS TOPICHOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICYIntroductionIncreased human epi...
Bendamustine-rituximab elicits dual tumoricidal and immunomodulatory responses via cGAS-STING activation in diffuse large B-cell lymphoma
IntroductionDiffuse large B-cell lymphoma (DLBCL) represents the predominant aggressive subtype among adult lymphomas, acc...
Correction: Targeting CD93 on monocytes revitalizes antitumor immunity by enhancing the function and infiltration of CD8+ T cells
To cite: Jiang D, Huang A, Zhu B-X, et al. Targeting CD93 on monocytes revitalizes antitumor immunity by enhancing the fun...
ICOS-expressing CAR-T cells mediate durable eradication of triple-negative breast cancer and metastasis
WHAT IS ALREADY KNOWN ON THIS TOPICThe success of blocking antibodies targeting CTLA-4 and programmed death receptor 1 in ...
Correlation of safety and efficacy of atezolizumab therapy across indications
WHAT IS ALREADY KNOWN ON THIS TOPICImproved overall survival (OS) has been demonstrated in patients receiving immune check...
Differences in the pathological, transcriptomic, and prognostic implications of lymphoid structures between primary and metastatic cutaneous melanomas
WHAT IS ALREADY KNOWN ON THIS TOPICWHAT THIS STUDY ADDSThis study reports the first assessment of heterogeneous presence o...
Correction: Inhibition of PNCK inflames tumor microenvironment and sensitizes head and neck squamous cell carcinoma to immune checkpoint inhibitors
Ding Q, Weng Y, Li Y, et al. Inhibition of PNCK inflames tumor microenvironment and sensitizes head and neck squamous cell...
Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT study
WHAT IS ALREADY KNOWN ON THIS TOPICAntiprogrammed cell death protein 1 (anti-PD-1) immune checkpoint inhibitors such as pe...
Reporting of late-onset immune-related adverse events with immune checkpoint inhibitors in VigiBase
IntroductionSince marketing authorization of the first-in-class ipilimumab in 2011 by the Food and Drug Administration (FD...
Myeloid subsets impede the efficacy of anti-PD1 therapy in patients with advanced gastric cancer (WJOG10417GTR study)
IntroductionGastric cancer (GC) is the fifth most common malignancy worldwide and the third-leading cause of cancer-relate...
Cancer-associated fibroblasts shape early myeloid cell response to chemotherapy-induced immunogenic signals in next generation tumor organoid cultures
BackgroundMonocytic myeloid cells are a highly plastic immune cell subset, capable of directing a wide variety of immune a...
Intratumoral and peritumoral radiomics of MRIs predicts pathologic complete response to neoadjuvant chemoimmunotherapy in patients with head and neck squamous cell carcinoma
WHAT IS ALREADY KNOWN ON THIS TOPICNeoadjuvant chemoimmunotherapy (NACI), combining traditional chemotherapy with an anti-...
In situ endoscopic photodynamic therapy combined with immature DC vaccination induces a robust T cell response against peritoneal carcinomatosis
IntroductionAnticancer dendritic cell (DC) vaccination is an immunotherapeutic approach that harnesses the power of the bo...
Role of CD47 gene expression in colorectal cancer: a comprehensive molecular profiling study
IntroductionCancer immunotherapies targeting adaptive immune checkpoints, such as programmed cell death protein-1, program...
WWOX tuning of oleic acid signaling orchestrates immunosuppressive macrophage polarization and sensitizes hepatocellular carcinoma to immunotherapy
BackgroundPrimary liver cancer is the sixth most commonly diagnosed cancer and the third-leading cause of cancer death, wi...
TMED inhibition suppresses cell surface PD-1 expression and overcomes T cell dysfunction
Materials availabilityInformation and materials can be obtained from the lead contact, Daniel S Peeper, on reasonable requ...
Body mass index and type 2 diabetes mellitus as metabolic determinants of immune checkpoint inhibitors response in melanoma
IntroductionImmune checkpoint inhibitors (ICIs) have revolutionized cancer treatment in recent years and have significantl...
SPI1+CD68+ macrophages as a biomarker for gastric cancer metastasis: a rationale for combined antiangiogenic and immunotherapy strategies
IntroductionOwing to its high incidence and metastatic rate, gastric cancer (GC) remains one of the poorly prognosis malig...
Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial
WHAT IS ALREADY KNOWN ON THIS TOPICAs a “me-too” antibody related to rituximab, the recombinant human-mouse chimeric anti-...
Leveraging mitochondrial-programmed cell death dynamics to enhance prognostic accuracy and immunotherapy efficacy in lung adenocarcinoma
IntroductionMalignant lung tumors are the most common malignant tumors of the respiratory system and the leading cause of ...
Targeting CDCP1 boost CD8+ T cells-mediated cytotoxicity in cervical cancer via the JAK/STAT signaling pathway
IntroductionAffecting women worldwide, cervical cancer ranks fourth in both incidence and mortality among gynecological tu...
Ten challenges and opportunities in computational immuno-oncology
Clinical trial designThe design of IO trials is critical to determining the best strategy for assessing the safety and eff...
Minority report on cancer immunotherapy: focus on elderly and other understudied populations
Over the past decade, immune therapy has transformed the therapeutic landscape in cancer, and is now well established as a...
TGF-{beta} trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistance
IntroductionAs of June 1, 2024, when the ASCO abstract was presented, the overall objective response rate (ORR) on the BET...
阅读更多
format_indent_increase